Objective: The purpose of this study is to use updated data and Bayesian methods to evaluate the effectiveness of hyperoxia to reduce surgical site infections (SSIs) and/or mortality in both colorectal and all surgery patients. Because few trials assessed potential harms of hyperoxia, hazards were not included. Background: Use of hyperoxia to reduce SSIs is controversial. Three recent meta-analyses have had conflicting conclusions. Methods: A systematic literature search and review were performed. Traditional fixed-effect and random-effect meta-analyses and Bayesian metaanalysis were performed to evaluate SSIs and mortality. Results: Traditional meta-analysis yielded a relative risk of an SSI with hyperoxia among all surgery patients of 0.84 [95% confidence interval (CI): 0.73-0.97] and 0.84 (95% CI: 0.61-1.16) for the fixed-effect and randomeffect models, respectively. The probabilities of any risk reduction in SSIs among all surgery patients were 77%, 81%, and 83% for skeptical, neutral, and enthusiastic priors. The subset analysis of colorectal surgery patients increased the probabilities to 86%, 89%, and 92%. The probabilities of at least a 10% reduction were 57%, 62%, and 68% for all surgery patients and 71%, 75%, and 80% among the colorectal surgery subset. Conclusions: There is a moderately high probability of a benefit to hyperoxia in reducing SSIs in colorectal surgery patients; however, the magnitude of benefit is relatively small and might not exceed treatment hazards. Further studies should focus on generalizability to other patient populations or on treatment hazards and other outcomes.
increase in oxidative killing of surgical pathogens and a reduction in SSIs. 1, 2 In vitro data have suggested that hyperoxia has additional cellular and immunological effects such as enhancement of intracellular killing by increased production of reactive oxygen species and attenuation of the proinflammatory cytokine response. 3 However, because of conflicting results from randomized controlled trials [4] [5] [6] [7] [8] [9] [10] [11] and meta-analyses, [12] [13] [14] [15] perioperative supplemental oxygen has not been widely recommended or adopted. In fact, a recent randomized controlled trial evaluating a bundle of interventions in elective colorectal surgery patients, which included hyperoxia, resulted in an increase in SSIs when compared with conventional therapy. 16 However, the trial was not designed to evaluate the effect of individual interventions such as hyperoxia alone on SSIs; inclusion of an ineffective intervention and/or presence of an interaction between interventions could have occurred.
There have been at least 4 published meta-analyses, all of which have had slightly differing conclusions regarding the effectiveness of supplemental oxygen in reducing SSIs. Brar et al concluded that perioperative supplemental oxygen does not reduce SSIs but decreases mortality in colorectal surgery patients. 12 Al-Niaimi and Safdar reported that supplemental oxygen reduces SSIs in colorectal surgery patients but cannot be applied more widely to other patient populations due to heterogeneity between studies. 13 Chura et al concluded that hyperoxia reduces SSI in colorectal surgery patients and should be considered in other patients undergoing cleancontaminated procedures. 15 Qadan et al recommended perioperative supplemental oxygen therapy as a preventive strategy to reduce SSIs without restriction on the patient population. 14 The differences in the results of these meta-analyses may be related to the studies included, patients included, and the type of model used (fixed-effect versus random-effect). However, despite these differences, the point estimates (expressed as risk ratios) and 95% confidence intervals (CIs) for the risk ratios for SSIs were very similar between metaanalyses, which suggest differences in the interpretations of the results.
Three meta-analyses used a random-effect model to evaluate the relative risk reduction with perioperative oxygen supplementation in colorectal surgery patients. 12, 13, 15 The point estimates ranged from 0.69 to 0.74, the lower limits of the 95% CI ranged from 0.39 to 0.43, and the upper limits ranged from 1.10 to 1.43. 12, 13, 15 Although none of the results reached statistical significance as defined by a P value less than 0.05, none of the CIs excluded the possibility of a clinically significant reduction in SSIs. A P value greater than 0.05 identified using traditional (frequentist) statistics is often misinterpreted as excluding any effect. 17 Use of Bayesian methods to directly assess the probability of benefit may avoid this problem and help clinicians better interpret study findings. 17, 18 Bayesian methods are already widely accepted in evaluating the results of diagnostic tests and are increasingly being used to design, analyze, and interpret clinical trials. 17, 19 Frequentist approaches do not involve consideration of evidence from other relevant studies, leaving this to the reader to do. In contrast, Bayesian statistics address the previous evidence as a distribution of hypothesized treatment effects or prior distribution (or prior). Depending on the strength of this evidence, the center of the distribution may be neutral (ie, centered at no effect), enthusiastic (ie, shifted toward benefit), or skeptical (ie, shifted toward harm). Because of the limitations in the quality of the evidence and publication bias or other biases that may exaggerate the apparent benefit of treatment, neutral and skeptical priors are often both used. Using Bayes theorem, the prior probability distribution is combined with the data from the study. The result is a distribution of effects or posterior distribution (or posterior) that can be used to estimate the probabilities of any range of effects. Unlike conventional frequentist statistics, Bayesian methods can estimate the likelihood that perioperative oxygen supplementation in surgery patients reduces the risk of SSIs by more than a specific percentage (ie, 1%, 10%, or 25%). 17 Diamond and Kaul have devised a system for classifying clinical practice guidelines using Bayesian methods. 20 With the publication of additional randomized controlled trials, including a multicenter trial in laparotomy patients 9 and a single center trial in appendectomy patients, 11 we have conducted a Bayesian meta-analysis 21 to update the estimated treatment effect for SSIs (primary outcome) and mortality (secondary outcome) for all surgical trials and for the subgroup of colorectal surgery. We hypothesized that additional clinical trials are not necessary to demonstrate a reduction in SSIs from perioperative supplemental oxygen therapy.
METHODS

Eligibility Criteria
Studies were selected if they were randomized trials comparing perioperative supplemental oxygen or hyperoxia with standard oxygen concentrations or normoxia. Only trials that reported SSIs or wound infections as an outcome were included.
Search Strategy and Study Selection
MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched in June 2011. Search terms included "oxygen," "hyperoxia," "surgery," "wound," "infection," and "randomized controlled trial." Medical Subject Headings terms were also used, including "oxygen inhalation therapy," "oxygen/administration and dosage," "hyperoxia," and "surgical wound infection/prevention and control." Hand searches were also performed of abstracts from relevant meetings, including the Surgical Infection Society, and of the reference lists of pertinent review articles and meta-analyses. Clinical trial registries were also searched (ClinicalTrials.gov). Two authors, trained in literature searching techniques, performed the searches independently (L.S.K. and S.G.M.).
Data Collection
Data were extracted from the randomized controlled trials regarding SSIs and mortality by 2 reviewers (L.S.K. and S.G.M.).
Assessment of Risk of Bias in Individual Studies
All randomized controlled trials that met the eligibility criteria were assessed for quality by 2 reviewers and disagreements were resolved by discussion. The Jadad score, which evaluates randomized trials on how randomization was performed, blinding, and reporting of withdrawals and dropouts, was calculated for each trial (L.S.K. and S.G.M.). Study quality was assessed in regard to randomization, method of allocation concealment, blinding, and use of intent-totreat analysis, as described in the Cochrane Handbook (L.S.K. and K.P.L.). 22
Statistical Analyses
Pooled estimates of the outcomes (SSIs, mortality) were reported as risk ratios with 95% CIs. Both fixed-effect and randomeffect models were performed. When there is heterogeneity between studies, fixed-effect and random-effect models differ in the underlying assumption about the effects estimated by the individual studies and in the weighting of the studies. 22 Fixed-effect models assume that there is a common treatment effect and that each individual study is providing an estimate of this effect. Random-effect models assume that there is a distribution of effects (ie, that the treatment effect varies based on patient population or other factors) and that the estimated effects from individual studies represent random samples from this distribution. When there is significant heterogeneity between studies, the CIs will be wider with random-effect models. 22 Heterogeneity was assessed using the χ 2 statistic (P < 0.1) and the I 2 statistic. The latter ranges from 0% to 100%; increasing values indicate higher percentages of total variation across studies due to heterogeneity. Although the I 2 statistic is a useful tool in assessing heterogeneity across studies, the decisions of whether or not to perform a meta-analysis or other analyses to explore the heterogeneity remain subjective. Publication bias was assessed using a funnel plot. Statistical analyses were performed using RevMan, version 5.1.
A Bayesian meta-analysis was performed using a hierarchical model to account for between-study heterogeneity (see Supplemental Digital Content: Appendix: Bayesian Meta-Analysis, available at http://links.lww.com/SLA/A296). 23 All analyses were conducted in WinBUGS. We report posterior medians, 95% credible intervals for risk ratios, and posterior probabilities of treatment effect.
RESULTS
Results of Search Strategy
A total of 631 citations were identified in the aforementioned search ( Fig. 1) . After a manual review of abstracts, a total of 8 studies qualified for inclusion in the meta-analysis; the characteristics of each trial are listed in Table 1 . These 8 studies were randomized controlled trials comparing supplemental perioperative oxygen (FiO 2 of 80%) versus standard care (FiO 2 of 30%-35%) on the incidence of SSI. A total of 4778 patients were enrolled in these trials, with 2355 receiving supplemental perioperative oxygen. In 6 of the trials, supplemental oxygen was administered intraoperatively and for 2 hours postoperatively. 4, 6, 7, [9] [10] [11] The study by Belda et al continued supplemental oxygen for 6 hours postoperatively. 5 The study by Myles et al evaluated SSI as a secondary endpoint in the analysis of 70% nitrous oxide, 30% oxygen versus 80% oxygen, and 20% nitrogen given intraoperatively during major surgery lasting at least 2 hours. 8 Patients undergoing abdominal surgery for benign and malignant pathology, on both an acute and an elective basis, were included. Three trials included only those patients undergoing elective colorectal surgery, 4,5,7 and 3 trials recruited patients undergoing any major abdominal surgery. 6, 8, 9 One trial included only those patients undergoing open appendectomy 11 and 1 trial only evaluated patients undergoing elective Cesarean section. 10 In the studies by Pryor et al 6 and Meyhoff et al, 9 patients were stratified by the type of surgery.
The criteria for SSI varied between studies, and included predetermined clinical criteria, [6] [7] [8] 10 Centers for Disease Control criteria, 5, 9 positive wound cultures, 4 additional treatment, serous discharge, erythema, purulent discharge, separation of deep tissues, isolation of bacteria, and stay in hospital longer than 14 days. 11 Postoperative follow-up ranged between 7 and 30 days; SSI was diagnosed on or before the last day of follow-up. In each trial, the wounds were evaluated by a surgical investigator blinded to the treatment allocation. The incidence of SSI in each trial is presented in Table 1 . 
Ascertainment of Bias
Using the Jadad score, 2 trials 7,11 received a score other than 5, indicating that most trials used an adequate randomization scheme, blinded the patient and outcome assessor(s) adequately, and described dropouts and withdrawals 24 (Table 1 ). All 8 trials were stated to be randomized. One trial used a random-number table to generate the allocation sequence, 6 and 5 trials used a computer-generated randomnumber sequence. 4, 5, [8] [9] [10] Two trials assigned treatment arms using sealed envelopes, but neither trial described the exact method of sequence generation for these treatment assignments. 7, 11 The methods could have been appropriate randomization techniques but there is not enough information to judge. Six trials performed allocation concealment using sealed envelopes, 4-7,10,11 although only 1 trial mentioned that the envelopes were opaque. 5 Two trials used a telephone or central service to allocate treatment assignment. 8, 9 Both the sealed envelopes and the central randomization service were considered to be adequate methods of allocation concealment. Blinding was evaluated as pertained to the investigators, participants, outcome assessors, and data analysts. All of the studies stated that the outcome assessors were blinded to treatment assignment. Three studies did not specify whether or not the data analysts were blinded. 4,10,11 All but 1 of the studies described blinding of the investigators and participants. 7 All but 2 of the studies stated that an intention-to-treat analysis was performed; 7,11 1 of these 2 trials included all patients in the analysis but did not explicitly state that there was no loss to follow-up or withdrawal of patients. 11 Three of the studies using intention-to-treat analysis excluded patients after randomization. 5, 8, 9 A funnel plot is presented in Figure 2 for ascertainment of publication bias for the outcome of SSI. The funnel plot is roughly symmetrical and is centered on a relative risk less than 1, favoring hyperoxia. The precision of each trial is similar, with the exception of the Mayzler trial 7 that had the lowest sample size and is the bottom point on the funnel plot.
Primary Outcome-SSIs Traditional Analysis
When all randomized controlled trials were combined, supplemental oxygen resulted in a statistically significant reduction in SSIs using a fixed-effect model (risk ratio: 0.84, 95% CI: 0.73-0.97, P = model yielded an estimate of risk ratio = 0.78 (95% CI: 0.57-1.07, P = 0.12; Fig. 3B ). The similarity of the fixed-effect and randomeffect models suggests that there is little impact of small studies on the estimates of treatment effect. 22 There was substantial heterogeneity when studies of all patients were included (I 2 = 68%), with slightly less heterogeneity when only the subgroup of colorectal surgery patients was used (I 2 = 45%). Excluding the Mayzler trial, which had the lowest Jadad score, did not significantly change the estimates of treatment effect.
Bayesian Analysis
The risk ratio and 95% credible intervals were calculated for SSI reduction in all abdominal surgery patients and in colorectal surgery patients only using skeptical, neutral, and enthusiastic priors ( Table 2) . When all surgery patients were considered, the probability of any reduction in SSIs with hyperoxia ranged from 77% to 85%. If a treatment effect of a 10% or 20% reduction in SSIs was considered, the probabilities decreased significantly to 57% to 68% or 31% to 41%, respectively. For colorectal surgery patients only, the probability of any reduction in SSIs with hyperoxia ranged from 86% to 92%, depending upon whether a skeptical or an enthusiastic prior was used ( Fig. 4) . Exclusion of the Mayzler trial did not change the probabilities significantly.
Secondary Outcome-Mortality Traditional Analysis
Five of the trials evaluated mortality. All of the studies had a point estimate suggesting a reduction in mortality with hyperoxia, except for the Meyhoff study that had the largest number of participants and a point estimate suggesting a significant increase in mortality. Three of the trials had no deaths in 1 group. A meta-analysis was not performed because there were only a small number of studies with rare binary events and not enough information to estimate the between-study variability. 25
Bayesian Analysis
The probabilities of any reduction in mortality with hyperoxia with skeptical, neutral, and enthusiastic prior distributions were 59%, 70%, and 75%, respectively.
DISCUSSION
The use of hyperoxia to prevent SSIs remains controversial. A consensus statement on perioperative care after colorectal surgery by the Enhanced Recovery After Surgery Group does not mention hyperoxia, 26 whereas a recent review of nonpharmacological mechanisms for reducing SSIs in colorectal surgery concluded that hyperoxia has a beneficial, although limited effect, in reducing SSIs. 27 The latter review based their recommendation on an updated metaanalysis of the same randomized controlled trials included in this study and obtained a similar estimate of treatment effect (reported as an odds ratio rather than a risk ratio). On the other hand, the Guidelines for Implementation of Enhanced Recovery Protocols published by the Association of Surgeons of Great Britain and Ireland in 2009 recommend high inspired oxygen concentrations (80%) during anesthesia and for at least 6 hours postoperatively. 28 The recommendation is based not only on the results of the Qadan meta-analysis evaluating the effects of hyperoxia on SSIs but also on a meta-analysis citing a reduction in postoperative nausea and vomiting. 29 The Bayesian meta-analysis in this article provides a complementary interpretation of the results of traditional analytical methods. 17 Both the frequentist and the Bayesian meta-analyses support the use of hyperoxia to reduce SSIs, with Bayesian methods assigning a higher probability of benefit in colorectal surgery patients than in all other patients. The results of this study are similar to all 4 prior meta-analyses. [12] [13] [14] Although a real difference in outcome for colorectal surgery patients versus other types of surgery patients cannot be excluded, there is no obvious biological rationale for such a dif-ference. The subset analysis of colorectal surgery patients differed from the analysis of all patients largely due to the latter's inclusion of the Pryor trial, where the treatment effect favored normoxia in colorectal surgery patients, which increased when all patients were included, and the Gardella trial, which only enrolled Cesarean section patients. However, the Pryor trial has been previously criticized for methodological flaws such as imbalances between groups in potential effect modifiers like obesity (24% vs 11% of patients with body mass index >30 kg/m 2 in the hyperoxia group). 14 Both the Pryor and the Gardella trial were stopped early. The Pryor trial was stopped early due to harm (in this case, more SSIs in the normoxia group) and the Gardella trial was stopped early due to futility. Although predetermined stopping rules were used in both the cases, there are multiple reasons that stopping a trial early should be avoided such as implausibility of a large treatment effect (benefit or harm) and imprecision in the estimate of treatment effect. 30 In fact, systematic reviews have shown that stopping randomized trials early before benefit resulted in overestimation of treatment effect sizes. [31] [32] [33] This updated meta-analysis supports previous studies suggesting that the benefit from hyperoxia is likely modest, given that the probability of a 10% or greater relative risk reduction in SSIs in colorectal surgery patients was about 75%, but the probability of more than a 20% reduction was only about 50% (using a neutral point of view). Several of the trials were powered to detect much larger treatment effects such as the Meyhoff trial (33%) 9 and the Pryor trial (40%). 6 Meta-analysis allows a more precise estimate of treatment effect due to increased sample size, and Bayesian meta-analysis offers the additional advantage of being able to quantify the probability of benefit above specific thresholds.
The updated meta-analysis cannot make any conclusions about the effects of perioperative hyperoxia on mortality. There were only a small number of trials evaluating mortality as an endpoint and the outcome was rare. Furthermore, hyperoxia has been demonstrated to increase mortality in other patient populations such as depressed newborns 34 and patients resuscitated after cardiac arrest. 35 Given these findings, care should be given in extrapolating the results of this meta-analysis to other patient populations without further evaluation, such as emergency surgery patients who present in shock. The other potential clinical harms of hyperoxia that have been postulated include increased pulmonary complications, 9 impairment of glucose regulation, 36 and increased systemic vascular resistance resulting in a decreased cardiac output. 37, 38 The Meyhoff trial included pulmonary complications-specifically atelectasis, pneumonia, and respiratory failure-as secondary outcomes. There were no statistically significant differences in any of these outcomes, although again, clinically important differences cannot be excluded.
Bayesian posterior probabilities can be used to aid clinical decision making and formal guidelines. Diamond and Kaul have suggested a Bayesian schema for evidentiary classification of clinical practice guidelines that are based on probabilities for best-case and worst-case scenarios. 20 Using this schema, the "preponderance of evidence" supports the use of perioperative hyperoxia and would rate a recommendation for its use as having 3 of 5 stars for all patients. Using Bayesian probabilities, the strength of the recommendation can be determined across a spectrum of thresholds of clinical benefit. For example, if the clinician will only implement the intervention if it results in at least a 10% reduction in SSIs, the strength of the recommendation can be recalculated and altered accordingly.
The limitations of meta-analyses, both traditional and Bayesian, include questions of the appropriateness of combining heterogeneous studies. Other meta-analyses have performed sensitivity analyses such as excluding studies that did not include colorectal surgery patients and studies that did not use nitrous oxide to evaluate the source of the heterogeneity. 14 Specific to Bayesian methods, a criticism is the subjectivity used in determining the prior probability distributions. 19 However, when the data are strong, the influence of the prior distributions is minimal, 39 as can be observed by the consistency of estimates of treatment effect for reduction in SSIs.
In conclusion, both traditional and Bayesian meta-analyses provide support for perioperative hyperoxia to reduce SSIs in colorectal surgery patients and surgery patients. Bayesian methods can complement traditional frequentist approaches to synthesizing and interpreting data, particularly when the interpretation is controversial. Further studies on perioperative hyperoxia should focus on other patient populations and on better identifying and quantifying harms.
